Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Share-based Compensation (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Share-based Compensation for 12 consecutive years, with $11.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 61.85% to $11.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $61.6 million, a 43.83% decrease, with the full-year FY2025 number at $61.6 million, down 43.83% from a year prior.
  • Share-based Compensation was $11.8 million for Q4 2025 at Iovance Biotherapeutics, down from $11.9 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $31.0 million in Q3 2024 to a low of $11.8 million in Q4 2025.
  • A 3-year average of $19.5 million and a median of $16.3 million in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 115.13% in 2024, then tumbled 61.85% in 2025.
  • Iovance Biotherapeutics' Share-based Compensation stood at $14.4 million in 2023, then soared by 115.13% to $31.0 million in 2024, then crashed by 61.85% to $11.8 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Share-based Compensation are $11.8 million (Q4 2025), $11.9 million (Q3 2025), and $14.9 million (Q2 2025).